The Journal of Advances in Leukemia is a peer-reviewed, open access publication dedicated to publishing original research, reviews, clinical case reports, and translational studies on all aspects of leukemia and hematological malignancies. Our scope includes acute and chronic leukemias, lymphomas, myeloproliferative neoplasms, bone marrow transplantation, immunotherapy, targeted therapies, genomics, and biomarker discovery.

Our editorial board includes distinguished hematologists, oncologists, and research scientists from leading cancer centers and universities worldwide. We are committed to publishing high-quality research that advances understanding of disease mechanisms, improves diagnostic approaches, and accelerates development of more effective treatments. Membership supports editorial operations, peer review coordination, professional production, and long-term archiving of your important research contributions.

By becoming a member, you join a global community of clinicians and scientists working to improve outcomes for patients with blood cancers. Your membership directly supports the infrastructure that makes accessible, high-quality scholarly publishing possible in this critical therapeutic area.

Leukemia research requires specialized outlets that understand the complexities of hematological malignancies and the regulatory environment surrounding oncology drug development. Our dedicated editorial team and expert reviewers evaluate submissions with the clinical and scientific rigor that this field demands, while our membership program ensures that financial considerations never prevent important discoveries from reaching the clinicians and researchers who need them. Whether you are investigating novel therapeutic targets, reporting outcomes from CAR-T cell therapy trials, or studying the molecular pathways that drive leukemogenesis, membership ensures your work reaches its full potential audience.

We maintain rigorous ethical and methodological standards for all submissions. Authors must provide institutional ethics approvals for human subjects research, informed consent documentation, transparent conflict of interest disclosures including pharmaceutical relationships, and complete data availability statements. For clinical trials, registration in recognized registries (ClinicalTrials.gov, ISRCTN, etc.) is required. We encourage adherence to CONSORT for randomized trials, PRISMA for systematic reviews, STROBE for observational studies, and REMARK for tumor marker prognostic studies. Membership does not influence editorial decisions; all manuscripts undergo identical peer review.

Publishing leukemia research should accelerate scientific progress, not create financial barriers. Our membership program directly addresses the challenges researchers and clinicians face when sharing their findings with the global oncology community.

Select the membership tier that aligns with your publication volume and career stage. Whether you are an individual investigator conducting bench-to-bedside translational research, a graduate student developing your scientific portfolio, an academic department managing multiple faculty publications in hematology and oncology, or a pharmaceutical or biotechnology company sharing clinical trial results and drug development research, our membership tiers provide meaningful cost savings and dedicated author support throughout the entire publication lifecycle. Each tier includes access to our editorial guidance services, compliance support for regulatory requirements, and formal recognition of your commitment to advancing blood cancer research.

Email info@openaccesspub.org to start your membership application. Our team responds within 48 hours with next steps.

• Membership benefits apply during the active term and do not roll over unless specified in writing.
• Early renewal before expiration qualifies for a 20% discount on renewal fees.
• APC relief applies after peer review and formal acceptance, not upon submission.
• Membership does not guarantee acceptance; all manuscripts undergo standard expert review.